These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15855580)

  • 1. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.
    McMahon GT; Plutzky J; Daher E; Bhattacharyya T; Grunberger G; DiCarli MF
    Diabetes Care; 2005 May; 28(5):1145-50. PubMed ID: 15855580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.
    Naoumova RP; Kindler H; Leccisotti L; Mongillo M; Khan MT; Neuwirth C; Seed M; Holvoet P; Betteridge J; Camici PG
    J Am Coll Cardiol; 2007 Nov; 50(21):2051-8. PubMed ID: 18021872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC; Lin KD; Tien KJ; Tu ST; Hsiao JY; Chang SJ; Lin SR; Shing SJ; Chen HC
    Metabolism; 2010 Aug; 59(8):1139-44. PubMed ID: 20045142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    van der Meer RW; Rijzewijk LJ; de Jong HW; Lamb HJ; Lubberink M; Romijn JA; Bax JJ; de Roos A; Kamp O; Paulus WJ; Heine RJ; Lammertsma AA; Smit JW; Diamant M
    Circulation; 2009 Apr; 119(15):2069-77. PubMed ID: 19349323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
    Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
    J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Kong AP; Yamasaki A; Ozaki R; Saito H; Asami T; Ohwada S; Ko GT; Wong CK; Leung GT; Lee KF; Yeung CY; Chan JC
    Diabetes Obes Metab; 2011 Sep; 13(9):806-13. PubMed ID: 21492364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
    Clarke GD; Solis-Herrera C; Molina-Wilkins M; Martinez S; Merovci A; Cersosimo E; Chilton RJ; Iozzo P; Gastaldelli A; Abdul-Ghani M; DeFronzo RA
    Diabetes Care; 2017 Nov; 40(11):1530-1536. PubMed ID: 28847910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
    Karagiannis E; Pfützner A; Forst T; Lübben G; Roth W; Grabellus M; Flannery M; Schöndorf T
    Diabetes Technol Ther; 2008 Jun; 10(3):206-12. PubMed ID: 18473695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.
    Sourij H; Zweiker R; Wascher TC
    Diabetes Care; 2006 May; 29(5):1039-45. PubMed ID: 16644634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.